Sino Biopharm Signs $307 Million Deal with Inventiva for NASH Therapy
publication date: Sep 22, 2022
Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharm, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from France’s Inventiva in a $307 million deal. Lanifibranor, Inventiva’s lead candidate, is an oral small molecule that induces anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes. CTTQ will make a $12 million upfront payment and be responsible for up to $295 million in milestone payments, plus royalties. The company will either join the ongoing NATiV3 Phase III clinical trial of lanifibranor in NASH or run an independent study. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.